Recently released market study: Pipeline Insight: HIV - The Age of Convenience

New Pharmaceuticals research report from Datamonitor is now available from Fast Market Research
 
Dec. 12, 2009 - PRLog -- Three new partnerships are reshaping the competitive environment in HIV. Most notably, Tibotec/Johnson & Johnson is linking up with Gilead to combine their Phase III drug rilpivirine with Truvada to create a new gold standard fixed dose combination for treatment-naïve patients. Addressing Atripla's shortcomings, Datamonitor expects this product to dominate the market.

Scope

* In-depth analysis of Phase II and III clinical development compounds and comprehensive overview of Phase I drugs
* An overview of the key companies involved in the HIV pipeline, including an analysis of the new corporate alliances
* The epidemiology dynamics of HIV in the six major markets are discussed along with unmet needs that have evolved from the prolonged use of HAART
* Sales forecasts over the next 10 years for the each of the late-stage drugs

Highlights

Advances in antiretroviral therapy have addressed the two big unmet medical needs, resistance and safety. Convenience is the new frontier, pointing towards a bright future for cross-class fixed-dose combination, notably Gilead's Quad Pill and Gilead's and Johnson & Johnson's Truvada/rilpivirine combination.

Gilead's two new cross-class fixed dose combinations offer only moderate medical progress, but their added convenience compared with single ingredient formulations will cement the company's market leadership and reduce the market opportunity for single-ingredient formulations.

Abbott's monopoly in protease inhibitor boosting agents is nearing its end. At least three companies have pharmacokinetic enhancers with potentially improved safety profiles in clinical development, hopefully enabling the creation of more co-formulated brands

For more information or to purchase this report, go to http://www.fastmr.com/catalog/product.aspx?productid=43022

About Datamonitor

The Datamonitor Group is a world-leading provider of premium global business information, delivering independent data, analysis and opinion across the Automotive, Consumer Markets, Energy & Utilities, Financial Services, Logistics & Express, Pharmaceutical & Healthcare, Retail, Technology and Telecoms industries. Datamonitor's market intelligence products and services ensure that you will achieve your desired commercial goals by giving you the insight you need to best respond to your competitive environment.  View more research from Datamonitor at http://www.fastmr.com/catalog/publishers.aspx?pubid=1002

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
End
Source: » Follow
Email:***@fastmr.com Email Verified
Zip:01267
Tags:Rheumatoid, Arthritis, Trial, Clinical, Drug, Combination, Pipeline, Iia, Patients, Hiv
Industry:Medical, Research, Biotech
Location:Massachusetts - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Fast Market Research PRs
Trending News
Most Viewed
Top Daily News



Like PRLog?
9K2K1K
Click to Share